← Back to Clinical Trials
Recruiting NCT05994014

NCT05994014 PET/CT* vs. Cardiac CT for Detecting Coronary Atherosclerotic Disease [*PET: Positron Emission Tomography; CT: Computed Tomography]

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05994014
Status Recruiting
Phase
Sponsor Johns Hopkins University
Condition Coronary Artery Disease
Study Type INTERVENTIONAL
Enrollment 33 participants
Start Date 2023-07-01
Primary Completion 2026-06

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
PET/CT

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 33 participants in total. It began in 2023-07-01 with a primary completion date of 2026-06.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Early detection of coronary atherosclerotic disease facilitates adequate prevention. The purpose of this study is to compare an assessment of coronary atherosclerotic disease burden by positron emission tomography / computed tomography (NaF-PET/CT) with those of conventional and ultra-high-resolution-CT (UHR-CT) in patients with suspected coronary artery disease. For this purpose, the investigators plan to include 33 patients with symptoms concerning for CAD who have been referred for cardiac CT testing.

Eligibility Criteria

Inclusion Criteria: * Male or female patients * 18 years or older * referred for coronary CT angiography because of suspected coronary heart disease (CHD) with stable symptoms Exclusion Criteria: * The patient has a history of coronary heart disease, defined by prior myocardial infarction or prior coronary artery revascularization. * Pregnancy. * Atrial fibrillation. * Morbid obesity defines as a body mass index of \>40. * The patient has any other clinically significant medical condition that in the opinion of the Investigator could impact the patient's ability to successfully complete the trial.

Contact & Investigator

Central Contact

Armin A Zadeh, MD PhD MPH

✉ azadeh1@jhmi.edu

📞 410-502-0549

Principal Investigator

Armin Zadeh, MD PhD MPH

PRINCIPAL INVESTIGATOR

Johns Hopkins School of Medicine

Frequently Asked Questions

Who can join the NCT05994014 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Coronary Artery Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05994014 currently recruiting?

Yes, NCT05994014 is actively recruiting participants. Contact the research team at azadeh1@jhmi.edu for enrollment information.

Where is the NCT05994014 trial being conducted?

This trial is being conducted at Baltimore, United States.

Who is sponsoring the NCT05994014 clinical trial?

NCT05994014 is sponsored by Johns Hopkins University. The principal investigator is Armin Zadeh, MD PhD MPH at Johns Hopkins School of Medicine. The trial plans to enroll 33 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology